INTRODUCTION

Epidemiological data suggest that the prenatal environmental factors, including maternal immune activation (MIA), contribute to the onset of neuropsychiatric disorders such as autism spectrum disorder (ASD) and schizophrenia in offspring. There are a number of publications showing associations between maternal inflammatory biomarkers and these disorders. Meta-analyses suggest that...
maternal infection during pregnancy increases the risk of these disorders in offspring. Importantly, there are accumulating interests in the early prevention by anti-inflammatory compounds. However, there are no anti-inflammatory compounds that can be used in the early intervention for pregnant women with MIA. Polyriboinosinic-polyribocytidilic acid (poly[I:C]), a Toll-like receptor 3 agonist, is widely used as an animal model of MIA.

The Nuclear factor erythroid 2-related 2 (Nrf2) is a transcription factor which plays a crucial role in attenuating oxidative stress and inflammation. Sulforaphane (SFN) is a naturally occurring compound with potent anti-inflammatory effects. In addition, glucoraphanin (GF), glucosinolate precursor of SFN, is found in cruciferous vegetables. SFN attenuated abnormal behaviors in rodents after the administration of phencyclidine (PCP). Furthermore, the supplementation of GF during juvenile and adolescent stages prevented the behavioral abnormalities in adult mice after repeated PCP administration or MIA. These findings suggest that supplementation of GF may have prophylactic effects for neuropsychiatric disorders such as schizophrenia. However, there are currently no reports showing that supplementation of GF in pregnant rodents can affect the development of abnormal behaviors in juvenile and adult offspring after MIA.

This study was undertaken to investigate whether dietary intake of GF food pellets during pregnancy and lactation could attenuate the development of abnormal behaviors in juvenile and adult offspring after MIA.

MATERIALS AND METHODS

Animals

Pregnant ddY mice (embryo at the 5th day [E5], 9-10 weeks old) were obtained from Japan SLC Inc. Pregnant mice were caged into individually clear polycarbonate cage (22.5 × 33.8 × 14.0 cm) under a controlled 12/12h light-dark cycle (lights on from 07:00 am to 07:00 pm), with room temperature at 23 ± 1°C and humidity at 55 ± 5%. All mice had ad libitum access to water and food pellets. The experimental procedure using animals was approved by the Chiba University Laboratory Animal Care and Use Committee (permission number: 28-272).

Preparation of 0.1% GF and prenatal injection of poly(I:C)

Food pellets (CE-2; Japan CLEA, Ltd.) containing 0.1% glucoraphanin (GF) were prepared as reported previously. Normal food pellet or 0.1% GF food pellet was given to female mice during pregnancy and lactation (from E5 to P21 [weaning]). Subsequently, normal food pellets were given to all offspring mice from P21 to behavioral tests or PV immunohistochemistry.

The schedule of prenatal poly(I:C) treatment was performed as reported previously. The pregnant mice were injected intraperitoneally (i.p.) for six consecutive days from E12 to E17 with poly(I:C) (5.0 mg/kg/d, Sigma-Aldrich Co. Ltd.) or an equivalent saline (5 mL/kg). The male offspring were separated from their mothers at P21, and mice were caged each three to five in the groups.

Behavioral analysis

The novel object recognition test (NORT) and the three-chamber social interaction test were performed as reported previously.

PV immunohistochemistry

Parvalbumin immunohistochemistry using mouse polyclonal anti-parvalbumin (PV) antibody (1:100; abcam, ab11427) was performed as reported previously. The staining intensity of PV immunoreactivity in the inflalimbic (IL) and prelimbic (PrL) regions of mPFC was analyzed using a light microscope equipped with a CCD camera (Olympus IX70) and the SCION IMAGE software package. Images of sections (n = 4 for each mouse) within mPFC region were captured using a 100 × objective with a Keyence BZ-X700 microscope (Keyence Corporation).

Statistical analysis

All data are shown as mean ± standard error of the mean (SEM). The data were analyzed by two-way analysis of variance (ANOVA), followed post hoc Bonferroni test. Significance for results was set at P < .05.
FIGURE 1  Effects of 0.1% GF food pellet on cognitive deficits and social interaction deficits in the juvenile offspring after prenatal poly(I:C) exposure. A, Schedule of treatment and behavioral tests. Saline (5.0 mL/kg/d) or poly(I:C) (5.0 mg/kg/day from E12 to E17) was injected into pregnant mice. Normal food pellets or 0.1% GF food pellets were given to pregnant mice from E5 to P21. Subsequently, normal food pellets were given to all mice from P21. Behavioral tests such as novel object recognition test (NORT) and 3-chamber social interaction test were performed from P28 to P35. (B): NORT: There was no difference (two-way ANOVA: poly(I:C): F$_{1,39}$ = 0.122, P = .729, GF: F$_{1,39}$ = 0.073, P = .789, interaction: F$_{1,39}$ = 0.003, P = .954) between the four groups in the training session. In the retention session, two-way ANOVA showed the results (poly(I:C): F$_{1,39}$ = 37.73, P < .001, GF: F$_{1,39}$ = 2.039, P = .161, interaction: F$_{1,39}$ = 7.310, P = .010) between the four groups. In the retention test, the exploratory preference of poly(I:C) + GF food group was significantly higher than poly(I:C) + normal food group. **P < .05, ***P < .001 compared with poly(I:C) + normal food group. The value is expressed as the mean ± SEM (n = 10 or 11). (C): Three-chamber social interaction test. Left: Two-way ANOVA (empty: poly(I:C): F$_{1,31}$ = 0.641, P = .429, GF: F$_{1,31}$ = 4.423, P = .044, interaction: F$_{1,31}$ = 0.939, P = .340. stranger 1: poly(I:C): F$_{1,31}$ = 18.027, P < .001, GF: F$_{1,31}$ = 6.887, P = .013, interaction: F$_{1,31}$ = 10.371, P = .003). Right: Three-way ANOVA (stranger 1: poly(I:C): F$_{1,31}$ = 0.328, P = .571, GF: F$_{1,31}$ = 1.576, P = .219, interaction: F$_{1,31}$ = 0.761, P = .390. stranger 2: poly(I:C): F$_{1,31}$ = 9.509, P = .004, GF: F$_{1,31}$ = 0.434, P = .696, interaction: F$_{1,31}$ = 10.202, P = .003). Data are shown as mean ± SEM (n = 8 or 9). **P < .01. NS, not significant.
saline + normal food pellet group. Furthermore, the exploratory preference of the GF food pellet + poly(I:C) group was significantly higher than that of the normal food pellet + poly(I:C) group (Figure 1B).

In the three-chamber test, juvenile offspring after MIA showed social interaction deficits compared to the control group (Figure 1C). Dietary intake of 0.1% GF food pellet significantly improved social interaction deficits in juvenile offspring after MIA (Figure 1C). The data suggest that MIA causes ASD-like cognitive and social interaction deficits in juvenile offspring, and that dietary intake of 0.1% GF during pregnancy and lactation could prevent the onset of ASD-like behavioral abnormalities in juvenile offspring after MIA.

3.2 | Effects of dietary intake of 0.1% GF food pellets during pregnancy and lactation on cognitive deficits and reduction of PV immunoreactivity in the mPFC of adult offspring after MIA

We investigated the effects of dietary intake of 0.1% GF food pellets during pregnancy and lactation on cognitive deficits and reduction of PV immunoreactivity in the mPFC of adult offspring after MIA (Figure 2A). In the training session of NORT, there was no difference among the four groups (Figure 2B). In the retention session, two-way ANOVA showed the results (poly[I:C]: $F_{1,38} = 23.88, P < .001$, GF: $F_{1,38} = 52.19, P < .001$, interaction: $F_{1,38} = 35.57, P < .001$) between the four groups. In the retention test, the exploratory preference of poly[I:C] + GF food group was significantly higher than poly[I:C] + normal food group. ***$P < .001$ compared with poly[I:C] + normal food group. The value is expressed as the mean ± SEM ($n = 9$ or $11$).
significantly higher than that of the poly(I:C) + normal food pellet group (Figure 2B).

Furthermore, we performed PV immunohistochemistry at adulthood (11 weeks) (Figure 3A). PV immunoreactivity in the PrL (not IL) of the mPFC of the poly(I:C) + normal food pellet group was significantly lower than that in the saline + normal food pellet group. Furthermore, PV immunoreactivity in the PrL (not IL) of the mPFC of the poly(I:C) + GF food pellet group was significantly
higher than that in the poly(I:C) + normal food pellet group (Figure 3B,C).

These findings suggest that supplementation of 0.1% GF food pellets during pregnancy and lactation prevented the cognitive deficits and the reduction of PV immunoreactivity in the PrL of the mPFC in adult offspring after MIA.

4 | DISCUSSION

Here, we found that dietary intake of 0.1% GF food pellets during pregnancy and lactation prevented ASD- and schizophrenia-like behavioral abnormalities and reduction of PV immunoreactivity in the PrL of the mPFC in offspring after MIA. Therefore, it is likely that supplementation with GF-rich food in pregnant women with MIA (i.e., higher inflammation) could have prophylactic effects on the development of neurodevelopmental disorders in offspring.

We found cognitive deficits of juvenile offspring after MIA, consistent with previous reports.9-12 Given the role of cognitive impairment in ASD patients and subjects with a high risk for psychosis,25 it is likely that cognitive deficits may be a core behavioral deficit in juvenile offspring after MIA. Interestingly, dietary intake of 0.1% GF food pellet during pregnancy and lactation could block cognitive and social interaction deficits in juvenile offspring after MIA.

In this study, we also found reduction of PV immunoreactivity in the PrL, but not IL, of mPFC at adult offspring after MIA, consistent with the previous findings.9-12 Interestingly, dietary intake of 0.1% GF food pellet during pregnancy and lactation could prevent reduction of PV immunoreactivity in the PrL of mPFC of adult offspring after MIA. Prenatal infection may contribute to the onset of neurodevelopmental disorders in their offspring.1,2 Previously, we reported that dietary intake of 0.1% GF food pellet during juvenile and adolescence blocked the onset of cognitive deficits and reduction of PV immunoreactivity in the mPFC after repeated PCP administration.19 In addition, dietary intake of 0.1% GF food pellet during juvenile and adolescence blocked the onset of cognitive deficits and reduction of PV immunoreactivity in the mPFC of adult offspring after MIA.12 Furthermore, we also demonstrated that dietary intake of 0.1% GF food pellet might have prophylactic effects in chronic social defeat stress22 or inflammation,23 indicating a potent anti-inflammatory action of 0.1% GF food pellet. Collectively, it is likely that dietary intake of 0.1% GF pellet has beneficial effects in several animal models of psychiatric disorders.

Sedlak et al26 reported that SFN increased the endogenous antioxidant glutathione levels in the blood and brain of healthy human subjects, indicating potent antioxidant effect of SFN. Interestingly, a placebo-controlled, double-blind, randomized study showed that supplementation of SFN had beneficial effects in young people with ASD.27 A subsequent follow-up study showed that many parents and caregivers articulated the beneficial effects of SFN, both during the intervention phase and in the ensuing 3 years.28 Taken all together, it is likely that supplementation of GF (or SFN)-rich vegetables during pregnancy and lactation might have prophylactic effects on the development of neurodevelopmental disorders, such as ASD and schizophrenia.7

This manuscript has limitation. In this study, we did not investigate the tissue levels of GF and its metabolite SFN in the fetal brain. Therefore, it is unknown whether GF or SFN can affect directly altered cortical development of fetal brain after MIA. Further detailed study is needed.

In conclusion, the present data suggest that dietary intake of 0.1% GF during pregnancy and lactation could prevent the behavioral abnormalities in offspring after MIA. Finally, supplementation of GF (or SFN)-rich vegetables in pregnant women with MIA or pregnant women at high risk for psychosis might reduce the risk of onset of neurodevelopmental disorders in offspring.

ACKNOWLEDGMENTS

This work was supported by Japan Society for the Promotion of Science (to KH, 17H04243), Japan Agency for Medical Research and Development, (to KH, JP19dm0107119), and SENSHIN Medical Research Foundation, Japan (to KH).

CONFLICT OF INTEREST

Dr Hashimoto received speaker’s honoraria from Murakami Farm (Tokyo, Japan) which sells sulforaphane-rich vegetable. Drs. Ayumi Hirai, Shigenori Suzuki, and Hiroyuki Suganuma are employee of KAGOME which sells glucoraphanin-related products as the supplement. The other authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

KH is responsible for the design of the research and experiment and supervised the experimental analyses. KH wrote the paper. YF, AF, and TI performed behavioral experiments and immunohistochemistry. YF analyzed the data. AH, SS, and HS provided 0.1% GF food pellet. All authors read and approved this paper.

ANIMAL STUDIES

All animal experiments were approved by the Animal Care and Use Committee of Chiba University.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available in the Figure S1-S3 of this article.

ORCID

Kenji Hashimoto https://orcid.org/0000-0002-8892-0439

REFERENCES

1. Khandaker GM, Zimbron J, Lewis G, Jones PB. Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychol Med. 2013;43:239–57.
2. Brown AS, Meyer U. Maternal immune activation and neuropsychiatric illness: a translational research perspective. Am J Psychiatry. 2018;175:1073–83.
3. Jiang HY, Xu LL, Shao L, Xia RM, Yu ZH, Ling ZX, et al. Maternal infection during pregnancy and risk of autism spectrum disorders: a systematic review and meta-analysis. Brain Behav Immun. 2016;58:165–72.

4. Zhang J, Luo W, Huang P, Peng L, Huang Q. Maternal C-reactive protein and cytokine levels during pregnancy and the risk of selected neuropsychiatric disorders in offspring: a systematic review and meta-analysis. J Psychiatr Res. 2018;105:86–94.

5. Do KQ, Conus P, Cuenod M. Redox dysregulation and oxidative stress in schizophrenia: nutrigenetics as a challenge in psychiatric disease prevention. J Nutrigenet Nutrigenomics. 2010;101:131–53.

6. Sarris J, Logan AC, Akbaraly TN, Amminger GP, Balanza-Martinez V, Freeman MP, et al. Nutritional medicine as mainstream in psychiatry. Lancet Psychiatry. 2015;2:271–4.

7. Hashimoto K. Recent advances in the early intervention in schizophrenia: future direction from preclinical findings. Curr Psychiatry Rep. 2019;21:75.

8. Ozawa K, Hashimoto K, Kishimoto T, Shimizu E, Ishikura H, Iyo M. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry. 2006;59:546–54.

9. Fujita Y, Ishima T, Hashimoto K. Supplementation with D-serine prevents the onset of cognitive deficits in adult offspring after maternal immune activation. Sci Rep. 2016;6:37261.

10. Han M, Zhang JC, Yao W, Yang C, Ishima T, Ren Q, et al. Intake of 7,8-dihydroxyflavone during juvenile and adolescent stages prevents onset of psychosis in adult offspring after maternal immune activation. Sci Rep. 2016;6:30807.

11. Han M, Zhang JC, Huang XF, Hashimoto K. Intake of 7,8-dihydroxyflavone from pregnancy to weaning prevents cognitive deficits in adult offspring after maternal immune activation. Proc Natl Acad Sci USA. 2014;111:15550–5.

12. Matsuura A, Ishima T, Fujita Y, Iwayama Y, Hasegawa S, Kawahara-Miki R, et al. Dietary glucoraphanin prevents the onset of psychosis in adult offspring after maternal immune activation. Sci Rep. 2018;8:2158.

13. Haida O, Sagheer TA, Balbous A, Francheteau M, Matas E, Soria F, et al. Sex-dependent behavioral deficits and neuropathology in a maternal immune activation model of autism. Transl Psychiatry. 2019;9:124.

14. Ma M, Ren Q, Yang J, Zhang K, Xiong Z, Ishima T, et al. Key role of soluble epoxide hydrolase in the neurodevelopmental disorders of offspring after maternal immune activation. Proc Natl Acad Sci USA. 2019;116:7083–8.

15. Hashimoto K. Essential role of Keap1-Nrf2 signaling in mood disorders: overview and future perspective. Front Pharmacol. 2018;9:1182.

16. Yamamoto M, Kensler TW, Motohashi H. The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis. Physiol Rev. 2018;98:1169–203.

17. Fahey JW, Wade KL, Wehage SL, Holtclaw WD, Liu H, Talalay P, et al. Stabilized sulforaphane for clinical use: Phytochemical delivery efficiency. Mol Nutr Food Res. 2017;61:4.

18. Shirai Y, Fujita Y, Hashimoto K. Effects of the antioxidant sulforaphane on hyperlocomotion and prepulse inhibition deficits in mice after phencyclidine administration. Clin Psychopharmacol Neurosci. 2012;10:97–8.

19. Shirai Y, Fujita Y, Hashimoto R, Ohi K, Yamamori H, Yasuda Y, et al. Dietary intake of sulforaphane-rich broccoli sprout extracts during Juvenile and adolescence can prevent phencyclidine-induced cognitive deficits at adulthood. PLoS One. 2015;10:e0127244.

20. Lewis DA, Curley AA, Glausier JR, Volk DW. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012;35:57–67.

21. Pu Y, Yang J, Chang L, Qu Y, Wang S, Zhang K, et al. Maternal glyphosate exposure caused autism-like behaviors in offspring through increased expression of soluble epoxide hydrolase. Proc Natl Acad Sci USA. 2020. https://doi.org/10.1073/pnas.1922287117

22. Yao W, Zhang JC, Ishima T, Dong C, Yang C, Ren Q, et al. Role of Keap1-Nrf2 signaling in depression and dietary intake of glucoraphanin confers stress resilience in mice. Sci Rep. 2016;6:30659.

23. Zhang JC, Yao W, Dong C, Yang C, Ren Q, Ma M, et al. Prophylactic effects of sulforaphane on depression-like behavior and dendritic changes in mice after inflammation. J Nutr Biochem. 2017;39:134–44.

24. Pu Y, Qu Y, Chang L, Wang S, Zhang K, Ushida Y, et al. Dietary intake of glucoraphanin prevents the reduction of dopamine transporter in the mouse striatum after repeated administration of MPTP. Neuropsychopharmacol Rep. 2019;39:247–51.

25. Fusar-Poli P, Deste G, Smieskova R, Barlati S, Yung AR, Howes O, et al. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry. 2011;69:562–71.

26. Sedlak TW, Nucifora LG, Koga M, Shaffer LS, Higgs C, Tanaka T, et al. Sulforaphane augments glutathione and influences brain metabolites in human subjects: a clinical pilot study. Mol Neuropsychiatry. 2018;3:214–22.

27. Singh K, Connors SL, Macklin EA, Smith KD, Fahey JW, Talalay P, et al. Sulforaphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci USA. 2014;111:15550–5.

28. Lynch R, Diggins EK, Connors SL, Zimmerman AW, Singh K, Liu H, et al. Sulforaphane from broccoli reduces symptoms of autism: a follow-up case series from a randomized double-blind study. Glob Adv Health Med. 2017;6:2164957X17735826.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Fujita Y, Fujita A, Ishima T, et al. Dietary intake of glucoraphanin during pregnancy and lactation prevents the behavioral abnormalities in the offspring after maternal immune activation. Neuropsychopharmacol Rep. 2020;40:268–274. https://doi.org/10.1002/npr.2.12112